GLP-1s Treat A Genetic Disorder
22:33–23:46 · 73s
Yurth argues stopping GLP-1s in patients with FTO variants is like withholding a cystic fibrosis treatment—these drugs finally address their satiety signaling.
22:33–23:46 · 73s
Yurth argues stopping GLP-1s in patients with FTO variants is like withholding a cystic fibrosis treatment—these drugs finally address their satiety signaling.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.